INNOVATIVE SCIENTIFIC CONCEPT OF TOPICAL VIRUS GLYCOPROTEIN INHIBITORS INCORPORATED IN HYPEROSMOTIC GLYCEROL REVOLUTIONIZES FUTURE PROSPECTS IN THE TREATMENT OF VIRAL AND BACTERIAL THROAT INFECTIONS
Abstract
Pharyngitis is primarily a viral infection of the respiratory tract, followed by secondary bacterial invasion due to weakening of local defenses. Influenza A and rhinoviruses are principally involved, the influenza virus having much higher pathogenicity, however, than rhinoviruses which usually cause the common cough and cold without severe damage to the respiratory mucosa. Following initial infection, the virus enters the cells only for multiplication and almost all virulent virus particles subsequently produced are shed onto the throat surface. From the throat surface, the virions infect new healthy cells, damaging the throat mucosa, and creating a favorable ground for secondary bacterial colonization which is the cause of almost all symptoms of throat infection (sore throat, strep throat). The virus’ complex structure, its constant mutation, the variety of its surface glycoproteins, as well as the role of topical proteases helping virus entry and virus – bacteria symbiosis must all be taken into account in designing an effective treatment, acting on multiple parameters. As most viruses and all bacteria are present on the throat’s outer lining, treatment should be designed to act topically on the surface of the pharynx, which also minimizes side effects. Until 2012, no topical antiviral drugs were available and almost all treatment strategies were directed to relieve only the symptomatic manifestations of throat infections. Anti-influenza vaccination is still considered the best preventive measure, while the use of intracellular virus inhibitors is strictly limited to severe cases as they were not found to be very effective once throat infection is established. The recent development of non-specific topical virus glycoprotein inhibitors, incorporated in a filmogen glycerol solution for an increased duration of action, represents a breakthrough yet relatively simple scientific approach for the treatment of viral throat infections accompanied by secondary bacterial infection. In this review, we analyze the whole process of viral throat infection, virus – bacteria interactions on the throat surface, currently available treatments and their drawbacks, and this innovative therapeutic approach consisting in virus glycoprotein inhibitors in an osmotic solution, destined to totally change the future treatment of throat infections.
Keywords:
antiviral, influenza virus, osmotic, pharyngitis, tannins, throatDOI
https://doi.org/10.25004/IJPSDR.2014.060101References
1. Dhama K, Verma AK, Rajagunalan S, Deb R, Karthik K, Kapoor S, Mahima, Tiwari R, Panwar PK, Chakraborty S. Swine flu is back again: a review. Pak J Biol Sci. 2012 Nov 1; 15(21):1001-9.
2. Paget WJ, Balderston C, Casas I, et al. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Pediatr. 2010 August; 169(8): 997-1008. doi: 10.1007/s00431-010-1164-0 PMCID: PMC2890072
3. World health organization report on influenza; http://www.who.int/mediacentre/factsheets/2003/fs211/en/
4. Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral and Bacterial Interactions in the Upper Respiratory Tract. PLoS Pathog. 2013 January; 9(1): e1003057. PMCID: PMC3542149
5. Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs. 2010 Jul 30; 70(11):1349-62. doi: 10.2165/11537960-000000000-00000.
6. Saladino R, Barontini M, Crucianelli M, Nencioni L, Sgarbanti R, Palamara AT. Current advances in anti-influenza therapy. Curr Med Chem. 2010; 17(20):2101-40. PMID: 20423307
7. Nichols WG, Campbell AJP, Boeckh M. Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances. Clin Microbiol Rev. 2008 April; 21(2): 274-290. doi: 10.1128/CMR.00045-07 PMCID: PMC2292575
8. Al Hajjar S, McIntosh K. The first influenza pandemic of the 21st century. Ann Saudi Med. 2010 Jan-Feb; 30(1): 1-10. doi: 10.4103/0256-4947.59365 PMCID: PMC2850175
9. Foucher RA, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from block headed gulls. J Virol. 2005; 79:2814-22.
10. Suxiang Tong et al. New World Bats Harbor Diverse Influenza A Viruses. PLoS Pathogens. 2013 Oct; 9 (10): e1003657. doi:10.1371/journal.ppat.1003657.
11. US Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) United States, 2013-14. Website: http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm
12. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature. 2003; 442: 428-33.
13. Mehle A, Doudna AJ. A host of factors regulating influenza virus replication. Viruses. 2010; 2(2), 566-573.
14. Shrivastava R. A new therapeutic approach to neutralize throat surface proteases and virus glycoproteins simultaneously for the treatment of influenza virus infection. International Journal of Virology. 2011; 7: 53-63. doi: 10.3923/ijv.2011.5363.
15. Kido H, Okumura Y, Takahashi E, Pan HY, Wang S, Yao D, Yao M, Chida J, Yano M. Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. Biochim Biophys Acta. 2012 Jan; 1824(1): 186-94. doi:10.1016/j.bbapap.2011.07.001. Epub 2011 Jul 23.
16. Kido H. et al. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv. Enzyme Regul. 1996 ; 36: 325-347.
17. Kido H. et al. Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. J. Mol. Genet. Med. 2008 Nov 29; 3(1): 167-75.
18. Delboy M. G. et al. Cellular Proteasome activity facilitates herpes simplex virus entry at a postpenetration step. Virol. 2008; 82(7): 3381–3390.
19. König R. et al. Human host factors required for influenza virus replication. Nature. 2010 Feb. 11; 463(7282): 813-817.
20. Beppu Y. et al. Human Mucus Protease Inhibitor in Airway Fluids Is a Potential Defensive Compound against Infection with Influenza A and Sendai Viruses. J. Biochem. 1997; 121(2): 309-316.
21. Kido H. et al. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr. Pharm. Des.2007; 13(4): 405-414.
22. Palese P, Shaw ML. Orthomyxoviridae: The Viruses and their Replication. In: Fields Virology. Knipe DM, Howley PM (eds), 5th Edn, Lippincott Williams & Wilkins, Philadelpha, 2006, pp. 1647-1689
23. Nayak B, Kumar S, DiNapoli JM, Paldurai A, Perez DR, Collins PL, Samal SK. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol. 2010 Mar; 84(5):2408-20. doi: 10.1128/JVI.02135-09. Epub 2009 Dec. PMID: 20032181
24. Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2proteins. Virology. 2005 Nov 25; 342(2):215-27. Epub 2005 Oct 24. PMID: 16249012
25. Bouvier NM, Palese P. The biology of influenza virus virus. Vaccine. 2008 September 12; 26(Suppl 4): D49-D53. NIHMSID: NIHMS71066 PMCID: PMC3074182
26. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004; 78:12665-67.
27. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol. 2002; 12:159-66.
28. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004 Nov; 78(22):12665-7.
29. Sieczkarski SB, Whittaker GR. Viral entry. Curr Top Microbiol Immunol. 2005; 285:1-23.
30. Cros JF, Palese P. Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. Virus Res. 2003 Sep; 95(1-2): 3-12.
31. Watson KBH, Carville KMA, Bowman JBA, Jacoby P, Riley TV, et al. Upper respiratory tract bacterial carriage in aboriginal and non-aboriginal children in a semi-arid area of western Australia. Pediatr Infect Dis J. 2006; 25(9)782-79010.1097/01.inf.0000232705.49634.68.
32. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: The key to pneumococcal disease. Lancet Infect Dis. 2004; 4: 144-154.
33. Brogden KA, Guthmiller JM, Taylor CE. Human polymicrobial infections. Lancet. 2005; 365(9455):253–25510.1016/S0140-6736(05)17745-9.
34. Mackenzie G, Leach A, Carapetis J, Fisher J, Morris P. Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: Cross-sectional surveys in a population with high rates of pneumococcal disease. BMC Infect Dis. 2010; 10(1): 304.
35. Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M. Interference between streptococcus pneumoniae and staphylococcus aureus: In vitro hydrogen peroxide-mediated killing by streptococcus pneumoniae. J Bacteriol. 2006; 188(13): 4996-500110.1128/JB.00317-06.
36. Pericone CD, Overweg K, Hermans PWM, Weiser JN. Inhibitory and bactericidal effects of hydrogen peroxide production by streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun. 2000; 68(7): 3990-399710.1128/IAI.68.7.3990-3997.2000.
37. Shakhnovich EA, King SJ, Weiser JN. Neuraminidase expressed by streptococcus pneumoniae desialylates the lipopolysaccharide of neisseria meningitidis and haemophilus influenzae: A paradigm for interbacterial competition among pathogens of the human respiratory tract. Infect Immun. 2002; 70(12): 7161-716410.1128/IAI.70.12.7161-7164.2002.
38. Cundell D, Gerard N, Gerard C, Idanpaan-Heikkila I, Tuomanen E. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995; 377(6548): 435-438.
39. Weiser JN, Shchepetov M, Chong STH. Decoration of lipopolysaccharide with phosphorylcholine: A phase-variable characteristic of haemophilus influenzae. Infect Immun. 1997; 65: 943–950.
40. Goldenberg HB, McCool TL, Weiser JN. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis. 2004; 190(7): 1254-1263.
41. Lysenko E, Ratner A, Nelson A, Weiser J. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog. 2005; 1(1):e1.doi:10.1371/journal.ppat.0010001.
42. Lysenko ES, Lijek RS, Brown SP, Weiser JN. Within-host competition drives selection for the capsule virulence determinant of streptococcus pneumoniae. Curr Biol. 2010; 20(13): 1222-122610.1016/j.cub.2010.05.051.
43. Tan TT, Mörgelin M, Forsgren A, Riesbeck K. Haemophilus influenzae survival during complement-mediated attacks is promoted by moraxella catarrhalis outer membrane vesicles. J Infect Dis. 2007; 195(11): 1661-1670.
44. Pettigrew MM, Gent JF, Pyles RB, Miller AL, Nokso-Koivisto J, et al. Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. J Clin Microbiol. 2011; 49(11): 3750–375510.1128/JCM.01186-11.
45. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006; 19: 571-582.
46. Vareille M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: Soldier in the fight against respiratory viruses. Clin Microbiol Rev. 2011; 24: 210-229.
47. Hament J, Aerts PC, Fleer A, Van Dijk H, Harmsen T, et al. Direct binding of respiratory syncytial virus to pneumococci: A phenomenon that enhances both pneumococcal adherence to human epithelial cells and pneumococcal invasiveness in a murine model. Pediatr Res. 2005; 58(6): 1198-1203.
48. Avadhanula V, Rodriguez CA, DeVincenzo JP, Wang Y, Webby RJ, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol. 2006; 80(4): 1629-163610.1128/JVI.80.4.
49. Van der Sluijs KF, van Elden LJR, Nijhuis M, Schuurman R, Pater JM, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol. 2004; 172(12): 7603-7609.
50. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis. 1986; 134(5): 1040-1044.
51. Suzuki K, Bakaletz LO. Synergistic effect of adenovirus type 1 and nontypeable haemophilus influenzae in a chinchilla model of experimental otitis media. Infect Immun. 1994; 62(5): 1710-1718.
52. van der Flier M, Chhun N, Wizemann T, Min J, McCarthy J, et al. Adherence of streptococcus pneumoniae to immobilized fibronectin. Infect Immun. 1995; 63(11): 4317-4322.
53. Tan TT, Nordström T, Forsgren A, Riesbeck K. The respiratory pathogen moraxella catarrhalis adheres to epithelial cells by interacting with fibronectin through ubiquitous surface proteins A1 and A2. J Infect Dis. 2005; 192(6): 1029-1038.
54. Sajjan U, Wang Q, Zhao Y, Gruenert DC, Hershenson MB. Rhinovirus disrupts the barrier function of polarized airway epithelial cells. Am J Respir Crit Care Med. 2008; 178(12): 1271-128110.1164/rccm.200801-136OC.
55. Pittet LA, Hall-Stoodley L, Rutkowski MR, Harmsen AG. Influenza virus infection decreases tracheal mucociliary velocity and clearance of streptococcus pneumoniae. Am J Respir Cell Mol Biol. 2010; 42(4): 450-46010.1165/rcmb.2007-0417OC.
56. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nat Rev Imm. 2003; 3: 710-720.
57. McGillivary G, Mason KM, Jurcisek JA, Peeples ME, Bakaletz LO. Respiratory syncytial virus-induced dysregulation of expression of a mucosal beta-defensin augments colonization of the upper airway by non-typeable haemophilus influenzae. Cell Microbiol. 2009; 11(9): 1399-140810.1111/j.1462-5822.2009.01339.x.
58. Jiang Z, Nagata N, Molina E, Bakaletz LO, Hawkins H, et al. Fimbria-mediated enhanced attachment of nontypeable haemophilus influenzae to respiratory syncytial virus-infected respiratory epithelial cells. Infect Immun. 1999; 67(1): 187-192.
59. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to nasal epithelial cells simultaneously. Laryngoscope. 2009; 119(7): 1406-141110.1002/lary.20498.
60. Ishizuka S, Yamaya M, Suzuki T, Takahashi H, Ida S, et al. Effects of rhinovirus infection on the adherence of streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis. 2003; 188(12): 1928-193910.1086/379833.
61. Wang JH, Lee SH, Kwon HJ, Jang YJ. Clarithromycin inhibits rhinovirus-induced bacterial adhesions to nasal epithelial cells. Laryngoscope. 2010; 120(1): 193–19910.1002/lary.20670.
62. Whiteman SC, Bianco A, Knight RA, Spiteri MA. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion Molecule–1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem. 2003; 278: 11954-11961.
63. Peltola VTP, Mccullers JA. Respiratory viruses predisposing to bacterial infections: Role of neuraminidase. Pediatr Infect Dis J. 2004; 23(1) (Supplement): S87-S97.
64. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and streptococcus pneumoniae. J Infect Dis. 2003; 187(6): 1000-1009.
65. Stark JM, Stark MA, Colasurdo GN, LeVine AM. Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J Med Virol. 2006; 78(6): 829-83810.1002/jmv.20631.
66. McNamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary streptococcus pneumoniae infection. Infect Immun. 2006; 74(12):6707-672110.1128/IAI.00789-06.
67. Engelich G, White M, Hartshorn KL. Neutrophil survival is markedly reduced by incubation with influenza virus and streptococcus pneumoniae: Role of respiratory burst. J Leukoc Biol. 2001; 69(1): 50-56.
68. Small C, Shaler CR, McCormick S, Jeyanathan M, Damjanovic D, et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol. 2010; 184(4): 2048-205610.4049/jimmunol.0902772.
69. Raza MW, Blackwell CC, Elton RA, Weir DM. Bactericidal activity of a monocytic cell line (THP-1) against common respiratory tract bacterial pathogens is depressed after infection with respiratory syncytial virus. J Med Microbiol. 2000; 49(3):227-233.
70. Kukavica-Ibrulj I, Hamelin M, Prince GA, Gagnon C, Bergeron Y, et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol. 2009; 83(3): 1341-134910.1128/JVI.01123-08.
71. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest. 2009; 119(7): 1910-192010.1172/JCI35412.
72. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med. 2008; 14(5): 558-56410.1038/nm1765.
73. Nicholson KG. Use of antivirals in influenza in the elderly: prophylaxis and therapy. Gerontology.1996; 42: 280-289.
74. Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1983 Nov; 26(5): 378-438.
75. Mia C K and Nancy P Lee. How to treat influenza and colds. West J Med. 2000 April; 172(4): 260-264. PMCID: PMC1070843
76. MIST Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-1881.
77. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-261.
78. Tamiflu Product Information. Roche Pharmaceuticals. Nutley, NJ. October 1999.
79. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013; 8(4): e60348. doi: 10.1371/journal.pone.0060348. Epub 2013 Apr 2.
80. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013 May; 98(2): 174-85. doi: 10.1016/j.antiviral.2013.03.014. Epub 2013 Mar 22.
81. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR 1998; 48(RR): 1-28.
82. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jan; 12(1): 36-44. doi: 10.1016/S1473-3099(11)70295-X.
83. Live attenuated influenza vaccine (LAIV). The nasal spray flu. US government information cdc.gov/flu/about/qa/nasalspray.html
84. Anonymous. WHO Model Prescribing Information. Drugs Used in the Treatment of Streptococcal Pharyngitis and Prevention of Rheumatic Fever Geneva, World health Organization. 1999. WHO/EDM?PAR/99.1.
85. Gooch WM 3rd. Alternatives to penicillin in the management of group a streptococcal pharyngitis. Pediatr Ann. 1992; 21(12): 810-815.
86. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2004; (2): CD000023.
87. Sheeler RD, Little P. Rapid streptococcal testing for sore throat and antibiotic resistance. Clin Microbiol Infect. 2006; 12(Suppl 9): 3-7.
88. Worrall G. Acute sore throat. Can Fam Physician. 2011 July; 57(7): 791-794.
89. Hayward G, Thompson M, Heneghan C, Perera R, Del Mar C, Glasziou P. Corticosteroids for pain relief in sore throat: systematic review and meta-analysis. BMJ. 2010 February 03; 340: c692. PMCID: PMC2722696.
90. Richards RN. Side effects of short-term oral corticosteroids. J Cutan Med Surg. 2008 Mar-Apr; 12(2): 77-81.
91. Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995 Feb; 162(2): 123-6.
92. Butler CC, Rollnick S, Kinnersley P, Jones A, Stott N. Reducing antibiotics for respiratory tract symptoms in primary care: consolidating 'why' and considering 'how'. Br J Gen Pract. 1998 December; 48(437): 1865-1870. PMCID: PMC1313298.
93. Hanif Palla A, Alam Khan R, Gilani AH, Marra F. Over prescription of antibiotics for adult pharyngitis is prevalent in developing countries but can be reduced using McIsaac modification of Centor scores: a cross-sectional study. BMC Pulm Med. 2012; 12: 70. doi: 10.1186/1471-2466-12-70. PMCID: PMC3517306.
94. Geist FC, Bateman JA, Hayden FG. In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother. 1987; 31: 622-624.
95. Salas M, Kirchner H. Induction of interferon-gamma in human leukocyte cultures stimulated by Zn2+. Clin Immunol Immunopathol. 1987; 45: 139-142.
96. Melchart D, Linde K, Worku F, et al. Immunomodulation with echinacea: a systematic review of controlled clinical trials. Phytomedicine. 1994; 1: 245-254.
97. Barrett B, Vohmann M, Calabrese C. Echinacea for upper respiratory infection. J Fam Pract1999; 48: 628-635.
98. Blumental M, et al. The complete German Commission E monographs: therapeutic guide to herbal medicines. American Botanical Council, Austin, TX, 1998.
99. Pepping J. Echinacea. Am J Health Syst Pharm. 1999; 56: 121-122.
100. Thompson A, Reader S, Field E, Shephard A. Open-label taste-testing study to evaluate the acceptability of both strawberry-flavored and orange-flavored amylmetacresol/2,4-dichlorobenzyl alcohol throat lozenges in healthy children. Drugs R D. 2013 Jun; 13(2): 101-7. doi: 10.1007/s40268-013-0012-x. PMID: 23588685
101. Vandamme L, Heyneman A, Hoeksema H, Verbelen J, Monstrey S. Honey in modern wound care: A systematic review. Burns. 2013 Jul 26. pii: S0305-4179(13)00197-6. doi: 10.1016/j.burns.2013.06.014. [Epub ahead of print]
102. León-Ruiz V, González-Porto AV, Al-Habsi N, Vera S, San Andrés MP, Jauregi P. Antioxidant, antibacterial and ACE-inhibitory activity of four monofloral honeys in relation to their chemical composition. Food Funct. 2013 Oct 24; 4(11): 1617-24. doi: 10.1039/c3fo60221d.
103. Maddocks SE, Jenkins RE. Honey: a sweet solution to the growing problem of antimicrobial resistance? Future Microbiol. 2013 Nov; 8: 1419-29. doi: 10.2217/fmb.13.105. PMID: 199801
104. Palaniappan S. Saltwater gargling. The Hindu, S&T, Science, Question Corner. 2012 October 31.
105. Emamian MH, Hassani AM, Fateh M. Respiratory Tract Infections and its Preventive Measures among Hajj Pilgrims, 2010: A Nested Case Control Study. Int J Prev Med. 2013 Sep; 4(9): 1030-5. PMID: 24130944
106. Turner, RB, Wecker MT, Pohl G, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection. JAMA 1999; 281: 1797-1804.
107. Shrivastava R, Deshmukh S, Rousse M. Comparison of a hypertonic tannin-rich solution vs 3% NaCl solution as treatment for rhinosinusitis. Am. J PharmTech Res. 2013; 3(2): 1-9.
108. Shrivastava R. Associating a hypertonic solution with specific plant procyanidins for the treatment of genital herpes. J Pharma & Sci Innovation. 2 (1) 47-51, 2013.
109. Anonymous. Docosanol: new drug. Herpes labialis: barely more effective than an excipient. Prescrire Int. 2009 Jun; 18(101): 106-7
110. Shaw M, King M, Best JM, Banatvala JE, Gibson JR, Klaber MR. Failure of acyclovir cream in treatment of recurrent herpes labialis. Br Med J (Clin Res Ed). 1985 Jul 6; 291(6487): 7-9.
111. Spruance SL, Crumpacker CS. Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit. Am J Med. 1982 Jul 20; 73(1A): 315-9.
112. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013 May; 98(2): 174-85. doi: 10.1016/j.antiviral.2013.03.014. Epub 2013 Mar 22.
113. Zambon MC. Surveillance for antiviral resistance. Influenza Other Respir Viruses. 2013 Jan; 7 Suppl 1: 37-43. doi: 10.1111/irv.12050.
114. Andrei G, Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis. 2013 Dec; 26(6): 551-60. doi: 10.1097/QCO.0000000000000015.
115. Greiff L, Andersson M, Wollmer P & Persson CGA. Hypertonic saline increases secretory and exudative responsiveness of human nasal airway in vivo. Eur Respir J. 2003; 21: 308-312. ISSN: 0903-1936. DOI: 10.1183/09031936.03.00290303
116. Shrivastava R. Non-solid composition for local application. Patent PCT/FR99/01340, International publication N°WO 00/74668 A1 on 14/12/2000.
117. Shrivastava Remi and Shrivastava Lea. A filmogen glycerol for topical application. International PCT patent PCT/EP2013/061835 dated 07/06/2013. Filed.
118. Lorenz MM, Alkhafadji L, Stringano E, Nilsson S, Mueller-Harvey I, Udén P. Relationship between condensed tannin structures and their ability to precipitate feed proteins in the rumen. J Sci Food Agric. 2013 Aug 12. doi: 10.1002/jsfa.6344. [Epub ahead of print]
119. Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol. 2011 May; 85(9): 4386-98.
120. Ueda K, Kawabata R, Irie T, Nakai Y, Tohya Y, Sakaguchi T. Inactivation of pathogenic viruses by plant-derived tannins: strong effects of extracts from persimmon (Diospyros kaki) on a broad range of viruses. PLoS One. 2013; 8(1): e55343. doi:10.1371/journal.pone.0055343. Epub 2013
121. Shrivastava R. New synergistic compositions for the treatment of topical viral infections. Patent PCT/EP2010/050236, International publication N° WO 2011/082835 A1 on 14/07/2011.
122. Shrivastava R, Deshmuks S. Clinical efficacy of a specific tannin rich osmotically active solution for the treatment of labial herpes. Int J Biol & Pharma Res. 2013; 4(4): 242-249. eISSN: 0976-3651.
123. Shrivastava R. A pilot clinical trial to evaluate the efficacy of a topical antiviral osmotically active hypertonic solution (VB-Th4) for the treatment of influenza virus induced sore throat. J Clinic Trials.2011; 1: 1-7. doi: 10.4172/jctr.1000102.
124. Noah DL, Noah JW. Adapting global influenza management strategies to address emerging viruses. Am J Physiol Lung Cell Mol Physiol. 2013 Jul 15; 305(2): L108-17. doi: 10.1152/ajplung.00105.2013. Epub 2013 May 24.
125. Nollette KA. Antimicrobial resistance. J Am Acad Nurse Pract. 2000 Jul; 12(7): 286-96; quiz 297-9.
2. Paget WJ, Balderston C, Casas I, et al. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. Eur J Pediatr. 2010 August; 169(8): 997-1008. doi: 10.1007/s00431-010-1164-0 PMCID: PMC2890072
3. World health organization report on influenza; http://www.who.int/mediacentre/factsheets/2003/fs211/en/
4. Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral and Bacterial Interactions in the Upper Respiratory Tract. PLoS Pathog. 2013 January; 9(1): e1003057. PMCID: PMC3542149
5. Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs. 2010 Jul 30; 70(11):1349-62. doi: 10.2165/11537960-000000000-00000.
6. Saladino R, Barontini M, Crucianelli M, Nencioni L, Sgarbanti R, Palamara AT. Current advances in anti-influenza therapy. Curr Med Chem. 2010; 17(20):2101-40. PMID: 20423307
7. Nichols WG, Campbell AJP, Boeckh M. Respiratory Viruses Other than Influenza Virus: Impact and Therapeutic Advances. Clin Microbiol Rev. 2008 April; 21(2): 274-290. doi: 10.1128/CMR.00045-07 PMCID: PMC2292575
8. Al Hajjar S, McIntosh K. The first influenza pandemic of the 21st century. Ann Saudi Med. 2010 Jan-Feb; 30(1): 1-10. doi: 10.4103/0256-4947.59365 PMCID: PMC2850175
9. Foucher RA, Munster V, Wallensten A, et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from block headed gulls. J Virol. 2005; 79:2814-22.
10. Suxiang Tong et al. New World Bats Harbor Diverse Influenza A Viruses. PLoS Pathogens. 2013 Oct; 9 (10): e1003657. doi:10.1371/journal.ppat.1003657.
11. US Recommendations: Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) United States, 2013-14. Website: http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm
12. Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature. 2003; 442: 428-33.
13. Mehle A, Doudna AJ. A host of factors regulating influenza virus replication. Viruses. 2010; 2(2), 566-573.
14. Shrivastava R. A new therapeutic approach to neutralize throat surface proteases and virus glycoproteins simultaneously for the treatment of influenza virus infection. International Journal of Virology. 2011; 7: 53-63. doi: 10.3923/ijv.2011.5363.
15. Kido H, Okumura Y, Takahashi E, Pan HY, Wang S, Yao D, Yao M, Chida J, Yano M. Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. Biochim Biophys Acta. 2012 Jan; 1824(1): 186-94. doi:10.1016/j.bbapap.2011.07.001. Epub 2011 Jul 23.
16. Kido H. et al. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv. Enzyme Regul. 1996 ; 36: 325-347.
17. Kido H. et al. Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. J. Mol. Genet. Med. 2008 Nov 29; 3(1): 167-75.
18. Delboy M. G. et al. Cellular Proteasome activity facilitates herpes simplex virus entry at a postpenetration step. Virol. 2008; 82(7): 3381–3390.
19. König R. et al. Human host factors required for influenza virus replication. Nature. 2010 Feb. 11; 463(7282): 813-817.
20. Beppu Y. et al. Human Mucus Protease Inhibitor in Airway Fluids Is a Potential Defensive Compound against Infection with Influenza A and Sendai Viruses. J. Biochem. 1997; 121(2): 309-316.
21. Kido H. et al. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr. Pharm. Des.2007; 13(4): 405-414.
22. Palese P, Shaw ML. Orthomyxoviridae: The Viruses and their Replication. In: Fields Virology. Knipe DM, Howley PM (eds), 5th Edn, Lippincott Williams & Wilkins, Philadelpha, 2006, pp. 1647-1689
23. Nayak B, Kumar S, DiNapoli JM, Paldurai A, Perez DR, Collins PL, Samal SK. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J Virol. 2010 Mar; 84(5):2408-20. doi: 10.1128/JVI.02135-09. Epub 2009 Dec. PMID: 20032181
24. Leser GP, Lamb RA. Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2proteins. Virology. 2005 Nov 25; 342(2):215-27. Epub 2005 Oct 24. PMID: 16249012
25. Bouvier NM, Palese P. The biology of influenza virus virus. Vaccine. 2008 September 12; 26(Suppl 4): D49-D53. NIHMSID: NIHMS71066 PMCID: PMC3074182
26. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004; 78:12665-67.
27. Wagner R, Matrosovich M, Klenk HD. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol. 2002; 12:159-66.
28. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol. 2004 Nov; 78(22):12665-7.
29. Sieczkarski SB, Whittaker GR. Viral entry. Curr Top Microbiol Immunol. 2005; 285:1-23.
30. Cros JF, Palese P. Trafficking of viral genomic RNA into and out of the nucleus: influenza, Thogoto and Borna disease viruses. Virus Res. 2003 Sep; 95(1-2): 3-12.
31. Watson KBH, Carville KMA, Bowman JBA, Jacoby P, Riley TV, et al. Upper respiratory tract bacterial carriage in aboriginal and non-aboriginal children in a semi-arid area of western Australia. Pediatr Infect Dis J. 2006; 25(9)782-79010.1097/01.inf.0000232705.49634.68.
32. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: The key to pneumococcal disease. Lancet Infect Dis. 2004; 4: 144-154.
33. Brogden KA, Guthmiller JM, Taylor CE. Human polymicrobial infections. Lancet. 2005; 365(9455):253–25510.1016/S0140-6736(05)17745-9.
34. Mackenzie G, Leach A, Carapetis J, Fisher J, Morris P. Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: Cross-sectional surveys in a population with high rates of pneumococcal disease. BMC Infect Dis. 2010; 10(1): 304.
35. Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M. Interference between streptococcus pneumoniae and staphylococcus aureus: In vitro hydrogen peroxide-mediated killing by streptococcus pneumoniae. J Bacteriol. 2006; 188(13): 4996-500110.1128/JB.00317-06.
36. Pericone CD, Overweg K, Hermans PWM, Weiser JN. Inhibitory and bactericidal effects of hydrogen peroxide production by streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun. 2000; 68(7): 3990-399710.1128/IAI.68.7.3990-3997.2000.
37. Shakhnovich EA, King SJ, Weiser JN. Neuraminidase expressed by streptococcus pneumoniae desialylates the lipopolysaccharide of neisseria meningitidis and haemophilus influenzae: A paradigm for interbacterial competition among pathogens of the human respiratory tract. Infect Immun. 2002; 70(12): 7161-716410.1128/IAI.70.12.7161-7164.2002.
38. Cundell D, Gerard N, Gerard C, Idanpaan-Heikkila I, Tuomanen E. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature. 1995; 377(6548): 435-438.
39. Weiser JN, Shchepetov M, Chong STH. Decoration of lipopolysaccharide with phosphorylcholine: A phase-variable characteristic of haemophilus influenzae. Infect Immun. 1997; 65: 943–950.
40. Goldenberg HB, McCool TL, Weiser JN. Cross-reactivity of human immunoglobulin G2 recognizing phosphorylcholine and evidence for protection against major bacterial pathogens of the human respiratory tract. J Infect Dis. 2004; 190(7): 1254-1263.
41. Lysenko E, Ratner A, Nelson A, Weiser J. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog. 2005; 1(1):e1.doi:10.1371/journal.ppat.0010001.
42. Lysenko ES, Lijek RS, Brown SP, Weiser JN. Within-host competition drives selection for the capsule virulence determinant of streptococcus pneumoniae. Curr Biol. 2010; 20(13): 1222-122610.1016/j.cub.2010.05.051.
43. Tan TT, Mörgelin M, Forsgren A, Riesbeck K. Haemophilus influenzae survival during complement-mediated attacks is promoted by moraxella catarrhalis outer membrane vesicles. J Infect Dis. 2007; 195(11): 1661-1670.
44. Pettigrew MM, Gent JF, Pyles RB, Miller AL, Nokso-Koivisto J, et al. Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. J Clin Microbiol. 2011; 49(11): 3750–375510.1128/JCM.01186-11.
45. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006; 19: 571-582.
46. Vareille M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: Soldier in the fight against respiratory viruses. Clin Microbiol Rev. 2011; 24: 210-229.
47. Hament J, Aerts PC, Fleer A, Van Dijk H, Harmsen T, et al. Direct binding of respiratory syncytial virus to pneumococci: A phenomenon that enhances both pneumococcal adherence to human epithelial cells and pneumococcal invasiveness in a murine model. Pediatr Res. 2005; 58(6): 1198-1203.
48. Avadhanula V, Rodriguez CA, DeVincenzo JP, Wang Y, Webby RJ, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol. 2006; 80(4): 1629-163610.1128/JVI.80.4.
49. Van der Sluijs KF, van Elden LJR, Nijhuis M, Schuurman R, Pater JM, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol. 2004; 172(12): 7603-7609.
50. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis. 1986; 134(5): 1040-1044.
51. Suzuki K, Bakaletz LO. Synergistic effect of adenovirus type 1 and nontypeable haemophilus influenzae in a chinchilla model of experimental otitis media. Infect Immun. 1994; 62(5): 1710-1718.
52. van der Flier M, Chhun N, Wizemann T, Min J, McCarthy J, et al. Adherence of streptococcus pneumoniae to immobilized fibronectin. Infect Immun. 1995; 63(11): 4317-4322.
53. Tan TT, Nordström T, Forsgren A, Riesbeck K. The respiratory pathogen moraxella catarrhalis adheres to epithelial cells by interacting with fibronectin through ubiquitous surface proteins A1 and A2. J Infect Dis. 2005; 192(6): 1029-1038.
54. Sajjan U, Wang Q, Zhao Y, Gruenert DC, Hershenson MB. Rhinovirus disrupts the barrier function of polarized airway epithelial cells. Am J Respir Crit Care Med. 2008; 178(12): 1271-128110.1164/rccm.200801-136OC.
55. Pittet LA, Hall-Stoodley L, Rutkowski MR, Harmsen AG. Influenza virus infection decreases tracheal mucociliary velocity and clearance of streptococcus pneumoniae. Am J Respir Cell Mol Biol. 2010; 42(4): 450-46010.1165/rcmb.2007-0417OC.
56. Ganz T. Defensins: Antimicrobial peptides of innate immunity. Nat Rev Imm. 2003; 3: 710-720.
57. McGillivary G, Mason KM, Jurcisek JA, Peeples ME, Bakaletz LO. Respiratory syncytial virus-induced dysregulation of expression of a mucosal beta-defensin augments colonization of the upper airway by non-typeable haemophilus influenzae. Cell Microbiol. 2009; 11(9): 1399-140810.1111/j.1462-5822.2009.01339.x.
58. Jiang Z, Nagata N, Molina E, Bakaletz LO, Hawkins H, et al. Fimbria-mediated enhanced attachment of nontypeable haemophilus influenzae to respiratory syncytial virus-infected respiratory epithelial cells. Infect Immun. 1999; 67(1): 187-192.
59. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to nasal epithelial cells simultaneously. Laryngoscope. 2009; 119(7): 1406-141110.1002/lary.20498.
60. Ishizuka S, Yamaya M, Suzuki T, Takahashi H, Ida S, et al. Effects of rhinovirus infection on the adherence of streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis. 2003; 188(12): 1928-193910.1086/379833.
61. Wang JH, Lee SH, Kwon HJ, Jang YJ. Clarithromycin inhibits rhinovirus-induced bacterial adhesions to nasal epithelial cells. Laryngoscope. 2010; 120(1): 193–19910.1002/lary.20670.
62. Whiteman SC, Bianco A, Knight RA, Spiteri MA. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion Molecule–1 (ICAM-1) receptor to promote epithelial cell infectivity. J Biol Chem. 2003; 278: 11954-11961.
63. Peltola VTP, Mccullers JA. Respiratory viruses predisposing to bacterial infections: Role of neuraminidase. Pediatr Infect Dis J. 2004; 23(1) (Supplement): S87-S97.
64. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and streptococcus pneumoniae. J Infect Dis. 2003; 187(6): 1000-1009.
65. Stark JM, Stark MA, Colasurdo GN, LeVine AM. Decreased bacterial clearance from the lungs of mice following primary respiratory syncytial virus infection. J Med Virol. 2006; 78(6): 829-83810.1002/jmv.20631.
66. McNamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary streptococcus pneumoniae infection. Infect Immun. 2006; 74(12):6707-672110.1128/IAI.00789-06.
67. Engelich G, White M, Hartshorn KL. Neutrophil survival is markedly reduced by incubation with influenza virus and streptococcus pneumoniae: Role of respiratory burst. J Leukoc Biol. 2001; 69(1): 50-56.
68. Small C, Shaler CR, McCormick S, Jeyanathan M, Damjanovic D, et al. Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung. J Immunol. 2010; 184(4): 2048-205610.4049/jimmunol.0902772.
69. Raza MW, Blackwell CC, Elton RA, Weir DM. Bactericidal activity of a monocytic cell line (THP-1) against common respiratory tract bacterial pathogens is depressed after infection with respiratory syncytial virus. J Med Microbiol. 2000; 49(3):227-233.
70. Kukavica-Ibrulj I, Hamelin M, Prince GA, Gagnon C, Bergeron Y, et al. Infection with human metapneumovirus predisposes mice to severe pneumococcal pneumonia. J Virol. 2009; 83(3): 1341-134910.1128/JVI.01123-08.
71. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest. 2009; 119(7): 1910-192010.1172/JCI35412.
72. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med. 2008; 14(5): 558-56410.1038/nm1765.
73. Nicholson KG. Use of antivirals in influenza in the elderly: prophylaxis and therapy. Gerontology.1996; 42: 280-289.
74. Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1983 Nov; 26(5): 378-438.
75. Mia C K and Nancy P Lee. How to treat influenza and colds. West J Med. 2000 April; 172(4): 260-264. PMCID: PMC1070843
76. MIST Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-1881.
77. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-261.
78. Tamiflu Product Information. Roche Pharmaceuticals. Nutley, NJ. October 1999.
79. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013; 8(4): e60348. doi: 10.1371/journal.pone.0060348. Epub 2013 Apr 2.
80. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013 May; 98(2): 174-85. doi: 10.1016/j.antiviral.2013.03.014. Epub 2013 Mar 22.
81. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR 1998; 48(RR): 1-28.
82. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012 Jan; 12(1): 36-44. doi: 10.1016/S1473-3099(11)70295-X.
83. Live attenuated influenza vaccine (LAIV). The nasal spray flu. US government information cdc.gov/flu/about/qa/nasalspray.html
84. Anonymous. WHO Model Prescribing Information. Drugs Used in the Treatment of Streptococcal Pharyngitis and Prevention of Rheumatic Fever Geneva, World health Organization. 1999. WHO/EDM?PAR/99.1.
85. Gooch WM 3rd. Alternatives to penicillin in the management of group a streptococcal pharyngitis. Pediatr Ann. 1992; 21(12): 810-815.
86. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2004; (2): CD000023.
87. Sheeler RD, Little P. Rapid streptococcal testing for sore throat and antibiotic resistance. Clin Microbiol Infect. 2006; 12(Suppl 9): 3-7.
88. Worrall G. Acute sore throat. Can Fam Physician. 2011 July; 57(7): 791-794.
89. Hayward G, Thompson M, Heneghan C, Perera R, Del Mar C, Glasziou P. Corticosteroids for pain relief in sore throat: systematic review and meta-analysis. BMJ. 2010 February 03; 340: c692. PMCID: PMC2722696.
90. Richards RN. Side effects of short-term oral corticosteroids. J Cutan Med Surg. 2008 Mar-Apr; 12(2): 77-81.
91. Fisher DA. Adverse effects of topical corticosteroid use. West J Med. 1995 Feb; 162(2): 123-6.
92. Butler CC, Rollnick S, Kinnersley P, Jones A, Stott N. Reducing antibiotics for respiratory tract symptoms in primary care: consolidating 'why' and considering 'how'. Br J Gen Pract. 1998 December; 48(437): 1865-1870. PMCID: PMC1313298.
93. Hanif Palla A, Alam Khan R, Gilani AH, Marra F. Over prescription of antibiotics for adult pharyngitis is prevalent in developing countries but can be reduced using McIsaac modification of Centor scores: a cross-sectional study. BMC Pulm Med. 2012; 12: 70. doi: 10.1186/1471-2466-12-70. PMCID: PMC3517306.
94. Geist FC, Bateman JA, Hayden FG. In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother. 1987; 31: 622-624.
95. Salas M, Kirchner H. Induction of interferon-gamma in human leukocyte cultures stimulated by Zn2+. Clin Immunol Immunopathol. 1987; 45: 139-142.
96. Melchart D, Linde K, Worku F, et al. Immunomodulation with echinacea: a systematic review of controlled clinical trials. Phytomedicine. 1994; 1: 245-254.
97. Barrett B, Vohmann M, Calabrese C. Echinacea for upper respiratory infection. J Fam Pract1999; 48: 628-635.
98. Blumental M, et al. The complete German Commission E monographs: therapeutic guide to herbal medicines. American Botanical Council, Austin, TX, 1998.
99. Pepping J. Echinacea. Am J Health Syst Pharm. 1999; 56: 121-122.
100. Thompson A, Reader S, Field E, Shephard A. Open-label taste-testing study to evaluate the acceptability of both strawberry-flavored and orange-flavored amylmetacresol/2,4-dichlorobenzyl alcohol throat lozenges in healthy children. Drugs R D. 2013 Jun; 13(2): 101-7. doi: 10.1007/s40268-013-0012-x. PMID: 23588685
101. Vandamme L, Heyneman A, Hoeksema H, Verbelen J, Monstrey S. Honey in modern wound care: A systematic review. Burns. 2013 Jul 26. pii: S0305-4179(13)00197-6. doi: 10.1016/j.burns.2013.06.014. [Epub ahead of print]
102. León-Ruiz V, González-Porto AV, Al-Habsi N, Vera S, San Andrés MP, Jauregi P. Antioxidant, antibacterial and ACE-inhibitory activity of four monofloral honeys in relation to their chemical composition. Food Funct. 2013 Oct 24; 4(11): 1617-24. doi: 10.1039/c3fo60221d.
103. Maddocks SE, Jenkins RE. Honey: a sweet solution to the growing problem of antimicrobial resistance? Future Microbiol. 2013 Nov; 8: 1419-29. doi: 10.2217/fmb.13.105. PMID: 199801
104. Palaniappan S. Saltwater gargling. The Hindu, S&T, Science, Question Corner. 2012 October 31.
105. Emamian MH, Hassani AM, Fateh M. Respiratory Tract Infections and its Preventive Measures among Hajj Pilgrims, 2010: A Nested Case Control Study. Int J Prev Med. 2013 Sep; 4(9): 1030-5. PMID: 24130944
106. Turner, RB, Wecker MT, Pohl G, et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection. JAMA 1999; 281: 1797-1804.
107. Shrivastava R, Deshmukh S, Rousse M. Comparison of a hypertonic tannin-rich solution vs 3% NaCl solution as treatment for rhinosinusitis. Am. J PharmTech Res. 2013; 3(2): 1-9.
108. Shrivastava R. Associating a hypertonic solution with specific plant procyanidins for the treatment of genital herpes. J Pharma & Sci Innovation. 2 (1) 47-51, 2013.
109. Anonymous. Docosanol: new drug. Herpes labialis: barely more effective than an excipient. Prescrire Int. 2009 Jun; 18(101): 106-7
110. Shaw M, King M, Best JM, Banatvala JE, Gibson JR, Klaber MR. Failure of acyclovir cream in treatment of recurrent herpes labialis. Br Med J (Clin Res Ed). 1985 Jul 6; 291(6487): 7-9.
111. Spruance SL, Crumpacker CS. Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit. Am J Med. 1982 Jul 20; 73(1A): 315-9.
112. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 2013 May; 98(2): 174-85. doi: 10.1016/j.antiviral.2013.03.014. Epub 2013 Mar 22.
113. Zambon MC. Surveillance for antiviral resistance. Influenza Other Respir Viruses. 2013 Jan; 7 Suppl 1: 37-43. doi: 10.1111/irv.12050.
114. Andrei G, Snoeck R. Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis. 2013 Dec; 26(6): 551-60. doi: 10.1097/QCO.0000000000000015.
115. Greiff L, Andersson M, Wollmer P & Persson CGA. Hypertonic saline increases secretory and exudative responsiveness of human nasal airway in vivo. Eur Respir J. 2003; 21: 308-312. ISSN: 0903-1936. DOI: 10.1183/09031936.03.00290303
116. Shrivastava R. Non-solid composition for local application. Patent PCT/FR99/01340, International publication N°WO 00/74668 A1 on 14/12/2000.
117. Shrivastava Remi and Shrivastava Lea. A filmogen glycerol for topical application. International PCT patent PCT/EP2013/061835 dated 07/06/2013. Filed.
118. Lorenz MM, Alkhafadji L, Stringano E, Nilsson S, Mueller-Harvey I, Udén P. Relationship between condensed tannin structures and their ability to precipitate feed proteins in the rumen. J Sci Food Agric. 2013 Aug 12. doi: 10.1002/jsfa.6344. [Epub ahead of print]
119. Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol. 2011 May; 85(9): 4386-98.
120. Ueda K, Kawabata R, Irie T, Nakai Y, Tohya Y, Sakaguchi T. Inactivation of pathogenic viruses by plant-derived tannins: strong effects of extracts from persimmon (Diospyros kaki) on a broad range of viruses. PLoS One. 2013; 8(1): e55343. doi:10.1371/journal.pone.0055343. Epub 2013
121. Shrivastava R. New synergistic compositions for the treatment of topical viral infections. Patent PCT/EP2010/050236, International publication N° WO 2011/082835 A1 on 14/07/2011.
122. Shrivastava R, Deshmuks S. Clinical efficacy of a specific tannin rich osmotically active solution for the treatment of labial herpes. Int J Biol & Pharma Res. 2013; 4(4): 242-249. eISSN: 0976-3651.
123. Shrivastava R. A pilot clinical trial to evaluate the efficacy of a topical antiviral osmotically active hypertonic solution (VB-Th4) for the treatment of influenza virus induced sore throat. J Clinic Trials.2011; 1: 1-7. doi: 10.4172/jctr.1000102.
124. Noah DL, Noah JW. Adapting global influenza management strategies to address emerging viruses. Am J Physiol Lung Cell Mol Physiol. 2013 Jul 15; 305(2): L108-17. doi: 10.1152/ajplung.00105.2013. Epub 2013 May 24.
125. Nollette KA. Antimicrobial resistance. J Am Acad Nurse Pract. 2000 Jul; 12(7): 286-96; quiz 297-9.
Published
01-01-2014
Statistics
Abstract Display: 414 
PDF Downloads: 452
Dimension Badge
How to Cite
“INNOVATIVE SCIENTIFIC CONCEPT OF TOPICAL VIRUS GLYCOPROTEIN INHIBITORS INCORPORATED IN HYPEROSMOTIC GLYCEROL REVOLUTIONIZES FUTURE PROSPECTS IN THE TREATMENT OF VIRAL AND BACTERIAL THROAT INFECTIONS”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 6, no. 1, Jan. 2014, pp. 01-11, https://doi.org/10.25004/IJPSDR.2014.060101.
Issue
Section
Review Article
How to Cite
“INNOVATIVE SCIENTIFIC CONCEPT OF TOPICAL VIRUS GLYCOPROTEIN INHIBITORS INCORPORATED IN HYPEROSMOTIC GLYCEROL REVOLUTIONIZES FUTURE PROSPECTS IN THE TREATMENT OF VIRAL AND BACTERIAL THROAT INFECTIONS”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 6, no. 1, Jan. 2014, pp. 01-11, https://doi.org/10.25004/IJPSDR.2014.060101.
